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TITLE: 
Analysis of relation between hypoxia imaging using 18F-MISO-PET and tissue-based 
biomarkers in patients with head and neck tumours in the course of primary 
radiochemotherapy  
 
 
 
 
ABSTRACT: 
Background: Tumour hypoxia is associated with poor prognosis and outcome and can be 
visualized using 18F-MISO-PET imaging. The goal of this study was to evaluate the correlation 
between biological markers and biological imaging in a group of patients in whom a correlation 
between biological imaging and outcome has previously been demonstrated. 
Material and Methods: In a prospective pilot project, 16 patients with locally advanced cancer 
of the head and neck underwent 18F-MISO-PET scans before and during primary 
radiochemotherapy in addition to 18F-FDG-PET and CT. Tumour biopsies were stained for three 
tissue-based markers (Ku80, CAIX, CD44); in addition, HPV status was assessed. H-scores of 
marker expression were generated and the results were correlated with the biological imaging 
and clinical outcome. 
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Results: No statistically significant correlation was established between the H-scores for Ku80, 
CD44 and CAIX or between any of the H-scores and the imaging variables (tumour volume on 
18F-FDG-PET in ml, hypoxic subvolume as assessed by 18F-MISO-PET in ml, and SUVmax 
tumour / SUVmean muscle during the 18F-MISO-PET). A statistically significant negative 
correlation was found between CD44 H-score and HPV status (p=0.004). Cox regression analysis 
for overall survival and recurrence-free survival showed one significant result for CAIX being 
associated with improved overall survival (Hazard ratio 0.96 (0.93-1.00), p=0.047). 
Conclusion: Expression of Ku80, CAIX and CD44 as assessed by immunohistochemistry of 
tumour biopsies were not correlated to one another or the biological imaging data. However, 
there was a significant influence of CAIX on overall survival and between CD44 and HPV.  
 
 
 
 
 
 
KEYWORDS: 
tumour hypoxia; hypoxia imaging; biological imaging; head and neck cancer; 
immunohistochemistry 
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INTRODUCTION 
Cancer of the head and neck is a frequent malignancy with a median five-year survival of 
around 50% [1]. One important prognostic factor is tumour hypoxia, which has been shown to 
be associated with reduced therapeutic effect of radiotherapy and decreased overall survival 
[2][3]. This is explained by decreased sensitivity towards radiation and reduced accessibility for 
chemotherapy [1][4].  
Given the prognostic importance and the potential therapeutic consequences (e.g. alteration of 
radiotherapy, additional drugs), the analysis of tumour hypoxia has to be seen as an important 
research field. Novel imaging techniques, including biological imaging, can complement the 
information available for treatment planning so far and thus help to improve the therapeutic 
setting [5]. 
For hypoxia imaging, 18F-MISO-PET is probably the most commonly used and best validated 
tracer so far [4][6]. The possibility and feasibility of using hypoxia imaging in a clinical setting in 
head and neck cancer patients – e.g. as a template for dose painting – has already been shown 
[7][8][9]. Good correlation of hypoxia PET with data generated using pO2-polarography 
measurements in head and neck tumours have also been found [10]. In addition, there are 
recent works assessing the time-course of hypoxia over treatment [3][11][12]. Previously, we 
and others showed a strong predictive capacity of hypoxia imaging in a group of patients with 
squamous cell carcinoma of the head and neck (HNSCC) receiving primary radiochemotherapy 
and undergoing serial 18F-MISO-PET scans for tumour hypoxia imaging in addition to 18F-FDG-
PET [3][13]. 
On the other hand, the relation between tissue-based biomarkers and the information 
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gathered from biological imaging are not well understood and there are only few studies 
addressing this issue.  
The goal of this study is to evaluate the correlation between select tissue-based biological 
markers and data obtained from PET imaging as well as outcome parameters in the same group 
of patients, and thus to elucidate the relation between  
1. The expression of the selected tissue-based biomarkers and HPV status themselves.  
2. The expression of tissue-based biomarkers and hypoxia & metabolic imaging. 
3. The expression of tissue-based biomarkers and clinical outcome.   
As tissue-based biomarkers, we chose carbonic anhydrase IX (CAIX) as cellular correlate for 
tumour hypoxia, CD44 as putative stem cell marker, Ku80 which is involved in DNA double-
strand-brake repair and human papilloma virus (HPV), another well-known prognostic factor in 
head and neck cancer patients. 
The information gathered from these investigations was hypothesized to guide the use of the 
afore-mentioned tissue-based biomarkers in relation to the use of hypoxia and metabolic 
imaging.  
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MATERIAL AND METHODS 
Cohort 
16 patients with HNSCC were included in this study. A detailed characterisation of the study 
population is given elsewhere [13]. However, this study reports a cohort with an updated and 
prolonged follow-up. The primary tumour localisations (patient numbers in brackets) were oral 
cavity (1), oropharynx (7), hypopharynx (5) and larynx (3). The patients were treated with 
primary radiochemotherapy; the protocol consisted of a total dose of 70 Gy in five fractions per 
week over 7 weeks, and up to three concomitant cycles of cisplatin (weeks 1, 4 and 7). The 
protocols for the imaging study and the subsequent tumour sample analysis have been 
approved by the Ethics Committee of the Medical Center – University of Freiburg (EK 68/08 and 
EK 296/12, respectively) and were in accordance with the ethical standards of the Helsinki 
Declaration of 1975, as revised in 1983. Written informed consent had been given by all 
patients for participation in the imaging study and has been waived for the subsequent tumour 
sample and correlation analysis. 
Imaging and radiotherapy 
All patients received an 18F-FDG-PET scan, a planning CT and MRI before starting the 
treatment. Up to three 18F-MISO-PET scans were performed: before starting the treatment 
and in weeks two and five. For this analysis, only the pre-treatment scan has been incorporated 
into the analysis because of the closest temporal proximity to the tumour biopsy. Scans were 
done with Siemens ECAT EXACT 921 PET scanner (15 patients) and Philips Gemini TrueFlight 
PET/CT scanner (1 patient). The dose of 18F-MISO was 3.7 MBq/kg up to a maximum of 370 
MBq; image acquisition started 150 min after tracer injection. Scan duration was 35 min (3 
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frames at 10 min, followed by a 5 min transmission scan). Patients were immobilized identical 
to the radiation position with a head and neck mask. Having acquired the 18F-MISO-PET scans, 
these were co-registered with the CT scans (for the stand-alone ECAT scanner).  
Gross tumour volume (GTV) was defined according to the 18F-FDG-PET scan; an uptake 
exceeding 40% of the maximum standardized uptake value was set as threshold and the 
resulting volume was validated with the CT and MRI data by an experienced clinician judging 
clinically acceptable quality of co-registration and image alignment as well as accuracy of the 
volume delineation. Hypoxic volumes were defined as all voxels within the GTV with a ratio of 
standardized uptake value of the tumour to mean standardized uptake value in a contralateral 
normal tissue sphere of equal to or greater than 1.4 (normalized against blood activity 
measured in the left ventricle).  
Immunohistochemistry 
Tumour biopsies were taken by head and neck surgeons four to six weeks before initiation of 
treatment to confirm diagnosis. Tumour biopsies were analysed for marker expression and 
correlation analyses were performed. All tumour samples were formalin fixed and paraffin-
embedded using routine protocols. 2 µm sections of tumour biopsies were mounted on coated 
glass slide (Superfrost Plus, Langenbrinck) deparaffinised and rehydrated using a descending 
alcohol row. Heat induced antigen retrieval was performed using citrate buffer at pH 6.1 for 40 
minutes. After inhibition of endogenous peroxidase by H2O2 (5 minutes) primary antibodies 
(CAIX: Cell Signalling, monoclonal rabbit anti-human 1:100; CD44: Cell Signalling, monoclonal 
mouse anti-human 1:500; Ku 80: Cell Signalling rabbit anti-human, 1:300) were incubated for 
30 minutes. Primary antibody detection and visualization was performed with the DAKO FLEX 
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EnVision Kit using the rabbit linker (CAIX and Ku 80) and mouse linker (CD44) for 15 minutes 
followed by horseradish peroxidase (20 minutes) and diaminobenzidine (10 minutes). All slides 
were counterstained by hematoxilin, dehydrated in an ascending alcohol row and coverslipped. 
For microscopic analysis, all slides were digitized using a Panoramic Scan (3D Histech, Hungary). 
Visual assessment was performed using an H-score, thereby taking into account the respective 
percentages of regions with strong, moderate and weak staining and yielding a final score of 0 
to 300, as previously described [14].  
HPV-Analysis 
After microdissection of tumour tissue from marked histological slides, DNA was isolated using 
routine protocols. For detection of HPV specific DNA the Chipron HPV 3.5 LCD array kit (Chipron 
GmbH, Berlin, Germany) was used according to the supplier’s instructions, yielding a binary +/- 
score. Positive and negative controls were performed for each run. 
Statistical methods 
The analysis was divided into three groups: Correlation between tumour tissue variables (4 
variables, yielding 6 pairs), correlation between tumour tissue variables and imaging data (4 
times 3, yielding 12 pairs), and finally influence of tumour tissue variables on outcome 
parameters (namely overall survival and recurrence-free survival). For the first two groups, 
Pearson's product-moment correlation was performed to analyse the relation between the 
pairs of markers or parameters, respectively. For the third group, the Cox proportional Hazards 
model was used.   
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RESULTS 
16 patients were included in this project. Initial hypoxic tumour subvolume on the pre-
treatment 18F-MISO-PET scan varied from 1 to 73.8 ml with a mean of 15.8 ml and a median of 
11.3 ml. The initial ratio of SUVmax in the tumour to SUVmean in the muscle varied from 1.14 
to 2.41 with a mean of 1.9 and a median of 2.0.  
The development of the hypoxic imaging in the course of treatment – assessed by serial 
imaging – and also the relation of SUVmax and hypoxic subvolume in regard to clinical outcome 
are subject to a dedicated and more detailed analysis [13]. In short, it has been shown that all 
patients with residual hypoxia showed local recurrence, whereas none with completely 
resolving hypoxia did. However, due to tumour biopsies only taken once before commencing 
treatment, it was the goal of this research project to correlate the information available from 
the tumour biopsies with those obtainable with the closest temporal proximity (i.e. the first, 
pre-treatment imaging time point).  
Immunohistochemistry was performed for CAIX, Ku80 and CD44. Representative examples of 
the staining are given in FIGURE 1. In addition, HPV status was investigated via LCD-chip 
analysis. The immunohistochemistry staining was scored and a cumulative H-score calculated. 
These results are presented in detail in TABLE 1, combined with the outcome data and imaging 
parameters.  
The details of the results of the statistical analysis with regard to correlation between the 
tissue-based biomarkers and the biological imaging are given in TABLE 2. Pairwise correlation 
analysis between each of the H-scores for Ku80, CD44 and CAIX and between any of these H-
scores and each of the imaging variables showed no statistically significant correlation. The 
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imaging variables used for the analysis were the tumour volume on 18F-FDG-PET measured in 
ml, the hypoxic subvolumes as assessed by the 18F-MISO-PET measured in ml, and the ratio of 
SUVmax in the tumour and SUVmean in muscle during the 18F-MISO-PET scan. A statistically 
significant negative correlation was found between CD44 H-score and HPV status (r
2
 = -0.68, p = 
0.004). This result also remained statistically significant after Bonferroni-Holm adjustment for 
multiple testing. In addition to these correlation analysis, Cox regression analysis was 
performed to analyse the influence of the tissue-based biomarkers on overall survival and 
recurrence-free survival. These results are given in TABLE 3. Due to the limited number of 
patients with HPV-positivity (2 vs. 14), this parameter could not be included in the regression 
analysis. One statistically significant factor was found: CAIX, with a hazard ratio per unit of 0.96 
in overall survival (95% confidence interval 0.93-1.00) at a p-value of 0.047. This is also 
exemplified in FIGURE 2, where we show a Kaplan-Meier-curve for overall survival, when 
dichotomising at the median of CAIX. Of note, this is not a direct representation of the Cox 
proportional hazards model, but rather a different way of graphically representing the 
underlying result with regard to the influence of CAIX on survival.  
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DISCUSSION 
Evidence on the correlation between hypoxia and metabolic imaging, clinical outcome and the 
expression of surface markers in immunohistochemistry is scarce. We selected a small array of 
well-known and recently investigated markers and compared their expression in 
immunohistochemical / array techniques with PET and clinical data. 
CAIX is an endogenous marker of hypoxia. It has been described to be associated with reduced 
survival in head and neck and oral cavity tumour patients [15]. To our best knowledge, there 
are no data correlating CAIX and hypoxia imaging in humans. In a small study with DCE-MRI and 
H-MRS, CAIX was not significantly correlated with these imaging data [16]. In a large patient 
cohort, CAIX was significantly associated with cancer-specific and overall survival; however, 
there was no significant correlation between CAIX and pO2-polarography [17]. There is a recent 
study however, finding a weak correlation between HIF-1alpha and 18F-MISO-PET [18], which 
has been published after completion of this study. Earlier, others have shown that hypoxic 
volumes delineated with 18F-MISO-PET show high correlations with both CAIX and 
Pimonidazole staining using immunohistochemistry in a rat model [19]. However, in their study 
the whole tumour was excised and microscopically analysed, thus preventing the possibility of 
missing the hypoxic region, as given in the biopsies taken from the human trial subjects in our 
study. We found no correlation between CAIX and 18F-MISO-PET imaging – however, we did 
see a statistically significant reduction of hazard ratio in overall survival (p = 0.047). This finding 
is surprising, yet it is difficult to interpret given the unclear question of representability of the 
area of the tumour subject to immunohistochemical analysis.  
Human papilloma virus (HPV) infection has been shown to be a significant factor regarding 
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patient survival [20]. A recent study analysed the relation between HPV status and hypoxia, 
assessed using pre-treatment 18F-MISO-PET; the results in 63 patients with head and neck 
cancer showed that both HPV positive and negative tumours have a high prevalence of 
hypoxia. As expected, the outcome was worst for patients with HPV negative hypoxic tumours 
[21]. In our study, due to the small number of HPV-positive cases (2 vs. 14), no definite 
conclusions could be drawn in this regard. This fact also explains why it is difficult to interpret 
the statistically significant negative correlation between CD44 H-score and HPV status (p = 
0.004). On the other hand, HPV – as a positive prognostic factor – could also be a surrogate 
marker for stem cell enrichment within the tumour, with a higher stem cell enrichment also 
explaining worse prognosis (then again indicated by an increase in visibility of CD44).  
Ku80 is a protein involved in non-homologous end-joining, a part of DNA double-strand-break 
repair, which has recently been found to be associated with locoregional failure and increased 
mortality in head and neck tumours, especially when HPV-negative [22]. The fourth tissue-
based biomarker investigated in this study, CD44, is a putative stem-cell marker which has been 
correlated with local recurrence in laryngeal carcinoma [23]. However, our analysis revealed no 
statistically significant correlation between the markers mentioned above and the PET or 
clinical data. It be argues, however, that our statistical analysis is detecting a trend which is not 
significant due to the restricted sample size. In the case of overall survival, an increase in CD44 
and Ku80 seems to indicate a worse prognosis (p = 0.08 and p = 0.07, respectively). In both 
cases, this link could be seen as biologically plausible, taking into consideration the above-
mentioned studies of Moeller and de Jong [22][23].  
In summary, the tissue-based biomarkers included in this study are not correlated with one 
another (with the unclear exception of CD44 and HPV), with the imaging variables and/or the 
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outcome (again, with the surprising exception of CAIX).  
Some hypotheses regarding the majority of negative results regarding the correlation with 
imaging and the influence on survival will be presented here: 
First, the markers used in this study were only scored in one small biopsy obtained to confirm 
diagnosis of malignancy. Therefore, we were not able to account for intra-tumour 
heterogeneity, which has been identified as a major characteristic of solid tumours [24].  
Second, we only examined a relatively small patient number. This of course results in reduced 
statistical power and did not allow for more sophisticated statistical analysis. However, given 
that hypoxia imaging is still exclusively used for research purposes and only available in a 
limited number of centres, the number of patients undergoing 18F-MISO-PET imaging is 
generally quite small. A potential solution to this issue is establishing multi-centre data 
collection and combined analysis. The German Cancer Consortium (DKTK) is currently setting 
up a respective registry addressing these issues. The data to be collected there will offer 
interesting possibilities in the future. 
In summary, when comparing the evidence provided by other hypoxia imaging studies and the 
results of this study, it can be stated, that biological imaging is capable of independently 
predicting response, and thus adds value to the clinical setting. This has not been seen for the 
tissue-based biomarkers employed in this study. Also taking into account the difficulties in 
analysing markers obtained from a single biopsy, it can be hypothesized, that PET imaging may 
offer several advantages over information gained from single small biopsies despite its lower 
resolution: Biological imaging provides an comprehensive information from the tumour and 
adjacent lymph nodes, in contrast to a small sample biopsy, which only assesses a fraction of 
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tumour mass [25]; it is non-invasive and can therefore more easily be done serially; finally, in 
the future, it may offer a possibility to stratify patients to receive different forms of treatment 
[8]. 
 
CONCLUSION 
With this study we correlated biological imaging using 18F-MISO-PET and 18F-FDG-PET as well 
as clinical outcome data with immunohistochemistry and chip array data obtained from 16 
patients with head and neck tumours. No statistically significant, clinically directly relevant 
correlations were revealed. The findings of this exploratory study underline the need for large, 
prospective data collections, such as those put forward by the German Cancer Consortium 
(DKTK).  
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Table 1: Patient characteristics, imaging data (pre-treatment 18F-FDG-PET and 18F-MISO-PET) 
and cumulative H-score for immunohistochemistry staining for CAIX, Ku80 and CD44 as well as 
results of HPV Chip analysis for patients 1 to 16 
Patient-
No. 
Age Gender Location TNM Follow-
up 
(months) 
Local 
failure 
Death Volume 
FDG 
(ml) 
Volume 
MISO 
(ml) 
MISO 
SUVmax 
tumour / 
SUVmean 
muscle 
CD44 
- H-
score 
Ku80 
- H-
score 
CAIX 
- H-
score 
HPV-
Chip 
positive 
1 64 M oropharynx T4 N2b 77.1   26 7.4 2.2 300 180 15 0 
2 52 M oropharynx T4 N2c 7.3 recurrence tumour 20 14.9 2.4 300 210 5 0 
3 61 F oral cavity T4 N2c 0 no 
remission 
tumour 99 73.8 2.4 280 260 25 0 
4 75 F tonsil T2 N2c 0.6  other 24 4.7 1.6 280 240 20 0 
5 62 M larynx T4 N2c 35.1  second 
malignancy 
10 1.9 1.5 285 230 30 0 
6 48 M hypopharynx T4 N2c 6.3 recurrence tumour 29 17.2 2.4 300 270 45 0 
7 68 F base of 
tongue 
T3 N2c 73.7   11 10.3 1.7 250 270 0 1 
8 47 M oropharynx T4 N2c 12.3  metasasis 20 15 1.6 280 170 10 0 
9 71 M larynx T4 N2c 62.3   16 12.2 1.7 270 200 90 0 
10 69 M larynx T3 N2c 75.3   9 5.3 2.3 280 210 5 0 
11 66 M hypopharynx T3 N2c 44 recurrence  16 15.8 2.3 280 200 130 0 
12 51 M hypopharynx T3 N2c 5.9  other 25 2.9 1.5 295 240 5 0 
13 44 M hypopharynx T4 N2b 73.1   22 1 1.1 300 220 75 0 
14 61 M tonsil T4 N2c 66.5   35 19.8 1.9 270 120 65 1 
15 51 M tonsil T4 N2c 63.1   62 42 2.2 300 280 120 0 
16 44 M hypopharynx T4 N2c 8.3 recurrence tumour 15 8 2.1 285 280 15 0 
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Table 2: Pearson’s product-moment correlation between tumour tissue variables and between 
these variables and imaging 
 r
2
 df p-value (* = significant, also 
after Bonferroni-Holm 
adjustment) 
Correlation between tumour tissue variables (4 variables => 6 pairs) 
CD44 – Ku80 0.13 
 
14 0.62 
CD44 – CAIX  0.10  
 
14 0.72 
CD44 – HPV chip positive -0.68  14 0.0038 * 
Ku80 – CAIX  -0.09 
 
14 0.75 
Ku80 – HPV chip positive -0.25 
 
14 0.34 
CAIX – HPV chip positive -0.083 14 0.78 
Correlation between tumour tissue variables and imaging (4 times 3 = 12 pairs) 
CD44 – Volume FDG 0.16 
  
14 0.55 
CD44 – Volume MISO -0.02 
 
14 0.95 
CD44 – MISO SUVmax tu / 
SUVmean muscle 
0.18 
 
14 0.49 
Ku80 – Volume FDG 0.23 
 
14 0.39 
Ku80 – Volume MISO 0.23 
 
14 0.40 
Ku80 – MISO SUVmax tu / 
SUVmean muscle 
0.10 
 
14 0.72 
CAIX – Volume FDG 0.18 
 
14 0.51 
CAIX – Volume MISO 0.21 14 0.43 
 
CAIX – MISO SUVmax tu / 
SUVmean muscle 
0.04 
 
14 0.88 
HPV chip positive – Volume 
FDG 
-0.08 14 0.78 
HPV chip positive – Volume 
MISO 
-0.02  14 0.96 
HPV chip positive – MISO 
SUVmax tu / SUVmean muscle 
-0.11 14 0.68 
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Table 3: Cox proportional hazards model  
Tumour tissue variables and overall survival 
 
Cox model Hazard ratio per unit (95% confidence 
interval) 
 
p-value (* = significant) 
CD44 1.07 (0.99 – 1.14) 0.08 
Ku80 1.02 (1.00 – 1.05) 0.07 
CAIX 0.96 (0.93 – 1.00) 0.047 * 
Tumour tissue variables and recurrence-free survival 
 
Cox model Hazard ratio per unit (95% confidence 
interval) 
 
p-value 
CD44 1.03 (0.98 – 1.09) 0.21 
Ku80 1.01 (0.99 – 1.03) 0.18 
CAIX 0.98 (0.96 – 1.01) 0.14 
 
 
 
 
 
Figure 1: Immunohistochemical staining for CA IX (A), CD44 (B) and Ku80 (C). Of note the focal 
positivity for CA IX within the carcinoma (Objective magnification 10x). 
 
 
 
Figure 2: Kaplan-Meier curve for overall survival in relation to CAIX status (dichotomised at the 
median).  
 
 
  
Page 28 of 29
URL:http://mc.manuscriptcentral.com/SONC
Acta Oncologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
 
85x167mm (300 x 300 DPI)  
 
 
Page 29 of 29
URL:http://mc.manuscriptcentral.com/SONC
Acta Oncologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
 
179x172mm (96 x 96 DPI)  
 
 
Page 30 of 29
URL:http://mc.manuscriptcentral.com/SONC
Acta Oncologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
